Urinary Tract Infections (UTI) Therapeutics - Pipeline Assessment and Market Forecasts to 2018 On 18thNovember 2014
Summary The industry analysis specialist, has released its new report, Urinary Tract Infections (UTI) Therapeutics - Pipeline Assessment and Market Forecasts to 2018. The report is an essential source of information and analysis on the global Urinary Tract Infections Therapeutics market. The report identifies the key trends shaping and driving the global Urinary Tract Infections Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Urinary Tract Infections Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalDatas team of industry experts.
Browse Full Report @ http://www.jsbmarketresearch.com/healthcaremedical/r-urinary-tract-infections-uti-therapeutics-pipeline-assessment-andmarket-forecasts-135250 Scope The report provides information on the key drivers and challenges of the Urinary Tract Infections Therapeutics market. Its scope includes - Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Urinary Tract Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Infections Therapeutics market revenues data from 2005 to 2010, forecast for eight years to 2018. - Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes. - Analysis of the current and future competition in the seven key countries Urinary Tract Infections Therapeutics market. - Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. - Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Urinary Tract Infections Therapeutics market. - Analysis of key recent licensing and partnership agreements in Urinary Tract Infections Therapeutics market
Reasons to buy The report will enhance your decision making capability. It will allow you to - Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline. - Develop business strategies by understanding the trends shaping and driving the global Urinary Tract Infections Therapeutics market. - Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Urinary Tract Infections Therapeutics market in future. - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. - Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. - Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. - Whats the next big thing in the global Urinary Tract Infections Therapeutics market landscape? Identify, understand and capitalize. Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Other industries we cover: • • • • • • • • •
Advertising and Media Automotive and Parts Consumer Goods Healthcare and Medical Finance and Banking Food and Beverages Travel and Tourism Textiles and Clothing SWOT Analysis
Discounts on Market Research Reports till 31st December, 2014 For more inquiries, contact at +91 - 998 729 5242 / contact@jsbmarketresearch.com Table of Content 2 UTI Therapeutics - Introduction 2.1 Overview 2.2 Classification of UTI 2.2.1 Site of Infection 2.2.2 Based On Symptoms 2.2.3 Based on Recurrence 2.2.4 Based on Complicating Factors 2.2.5 Based on Origin of Infection 2.3 Epidemiology 2.4 Etiology 2.5 Risk Factors 2.6 Signs and Symptoms 2.7 Pathophysiology of UTI 2.8 Diagnosis and Treatment of UTI 2.9 GlobalData Pipeline Report Guidance 3 UTI Therapeutics - Market Characterization 3.1 UTI Therapeutics Market Size (2005-2010) - Global 3.2 UTI Therapeutics Market Forecast (2010-2018) - Global Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
3.3 UTI Therapeutics Market Size (2005-2010) - The US 3.4 UTI Therapeutics Market Forecast (2010-2018) - The US 3.5 UTI Therapeutics Market Size (2005-2010) - France 3.6 UTI Therapeutics Market Forecast (2010-2018) - France 3.7 UTI Therapeutics Market Size (2005-2010) - Germany 3.8 UTI Therapeutics Market Forecast (2010-2018) - Germany 3.9 UTI Therapeutics Market Size (2005-2010) - Italy 3.10 UTI Therapeutics Market Forecast (2010-2018) - Italy 3.11 UTI Therapeutics Market Size (2005-2010) - Spain 3.12 UTI Therapeutics Market Forecast (2010-2018) - Spain 3.13 UTI Therapeutics Market Size (2005-2010) - The UK 3.14 UTI Therapeutics Market Forecast (2010-2018) - The UK 3.15 UTI Therapeutics Market Size (2005-2010) - Japan 3.16 UTI Therapeutics Market Forecast (2010-2018) - Japan 3.17 Drivers and Barriers for the UTI Therapeutics Market 3.17.1 Drivers for the UTI Therapeutics Market 3.17.2 Barriers for the UTI Therapeutics Market 3.18 Key Events Impacting the Future Market 3.19 Opportunity and Unmet Need 3.20 Key Takeaway 4 UTI Therapeutics Market - Competitive Assessment 4.1 Overview 4.1.1 Strategic Competitor Assessment 4.2 Profiles of Commonly Used Products in the UTI Therapeutics Market 4.2.1 Ciprofloxacin 4.2.2 Doribax (doripenem) 4.2.3 Invanz (ertapenem sodium) 4.2.4 Levaquin (levofloxacin) 4.2.5 Fosfomycin tromethamine 4.2.6 Macrobid/Macrodantin (nitrofurantoin) 4.2.7 Bactrim/Septra (trimethoprim/sulfamethoxazole) 4.3 Key Takeaway 5 UTI Therapeutics Market - Pipeline Assessment 5.1 Overview 5.2 Strategic Pipeline Assessment 5.2.1 UTI Therapeutics - Phase III Pipeline 5.2.2 UTI Therapeutics - Phase II Pipeline 5.2.3 UTI Therapeutics Phase I Pipeline 5.3 UTI Pipeline by Mechanism of Action Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
5.4 UTI Technology Trends Analytical Framework 5.5 UTI Therapeutics - Late-stage Drugs under Clinical Development 5.6 Molecule Profile for Late-stage Drugs under Clinical Development 5.6.1 CXA-201 (CXA-101/tazobactam) 5.6.2 CAZ-AVI (Avibactam/ceftazidime) 5.7 Key Takeaway 6 UTI Therapeutics - Clinical Trials Mapping 6.1 Clinical Trials by Country (US, EU5 and Japan) 6.2 Clinical Trials by Phase 6.3 Clinical Trials by Trial Status 6.4 Overall Sponsors 6.5 Prominent Sponsors 6.6 Top Companies Participating in UTI Therapeutics Clinical Trials 7 UTI Therapeutics - Strategic Assessment 7.1 UTI Therapeutics - Implications for Future Market Competition 8 UTI Therapeutics - Future Players 8.1 Introduction 8.1.1 AstraZeneca PLC 8.1.2 Cubist Pharmaceuticals 8.1.3 Forest Laboratories 9 UTI Therapeutics - Licensing and Partnership Deals 10 UTI Therapeutics - Appendix 10.1 Definitions 10.2 Acronyms 10.3 Research Methodology 10.3.1 Coverage 10.3.2 Secondary Research 10.3.3 Forecasting 10.3.4 Primary Research 10.3.5 Expert Panel Validation 10.4 Contact Us 10.5 Disclaimer 10.6 Bibliography List Of Tables Table 1: UTI - Prevalence, Major Markets, 2010 Table 2: UTI Therapeutics Market, Global, Revenue ($bn), 2005-2010 Table 3: UTI Therapeutics Market, Global, Forecast ($bn), 2010-2018 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Table 4: UTI Therapeutics Market, The US, Revenue ($m), 2005-2010 Table 5: UTI Therapeutics Market, The US, Forecast ($bn), 2010-2018 Table 6: UTI Therapeutics Market, France, Revenue ($m), 2005-2010 Table 7: UTI Therapeutics Market, France, Forecast ($m), 2010-2018 Table 8: UTI Therapeutics Market, Germany, Revenue ($m), 2005-2010 Table 9: UTI Therapeutics Market, Germany, Forecast ($m), 2010-2018 Table 10: UTI Therapeutics Market, Italy, Revenue ($m), 2005-2010 Table 11: UTI Therapeutics Market, Italy, Forecast ($m), 2010-2018 Table 12: UTI Therapeutics Market, Spain, Revenue ($m), 2005-2010 Table 13: UTI Therapeutics Market, Spain, Forecast ($m), 2010-2018 Table 14: UTI Therapeutics Market, The UK, Revenue ($m), 2005-2010 Table 15: UTI Therapeutics Market, The UK, Forecast ($m), 2010-2018 Table 16: UTI Therapeutics Market, Japan, Revenue ($m), 2005-2010 Table 17: UTI Therapeutics Market, Japan, Forecast ($m), 2010-2018 Table 18: UTI Therapeutics - Phase III Pipeline Table 19: UTI Therapeutics - Phase II Pipeline Table 20: UTI Therapeutics Phase I Pipeline Table 21: UTI Therapeutics - Late-stage Drugs Under Clinical Development, 2011 Table 22: UTI Therapeutics - Clinical Trials by Country, 2011 Table 23: UTI Therapeutics - Clinical Trials by Phase, 2011 Table 24: UTI Therapeutics - Clinical Trials by Status, 2011 Table 25: UTI Therapeutics, Overall Sponsors, 2011 Table 26: UTI Therapeutics - Prominent Sponsors, 2011 Table 27: UTI Therapeutics - Top Companies Participating in Clinical Trials, 2011 Table 28: AstraZeneca Infectious Disease Pipeline, 2011 Table 29: Cubist Pharmaceuticals Infectious Disease Pipeline, 2011 Table 30: Forest Laboratories - Infectious Disease Pipeline, 2011 Table 31: Licensing and Partnership Deals List Of Figures Figure 1: Classification of UTI Figure 2: Principal Pathogens of UTI Figure 3: Symptoms of UTI Figure 4: Diagnostic Approach to UTI in Adults Figure 5: Different Class of Antibiotics Used for UTI Figure 6: Diagnosis and Treatment of UTI Figure 7: Diagnosis and Treatment of UTI Figure 8: UTI Therapeutics Market, Global, Revenue ($bn), 2005-2010 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Figure 9: UTI Therapeutics, Market Share ($m, %), 2010 Figure 10: UTI Therapeutics Market, Global, Forecast ($bn), 2010-2018 Figure 11: UTI Therapeutics, Market Share ($m, %), 2018 Figure 12: UTI Therapeutics Market, The US, Revenue ($m), 2005-2010 Figure 13: UTI Therapeutics Market, The US, Forecast ($bn), 2010-2018 Figure 14: UTI Therapeutics Market, France, Revenue ($m), 2005-2010 Figure 15: UTI Therapeutics Market, France, Forecast ($m), 2010-2018 Figure 16: UTI Therapeutics Market, Germany , Revenue ($m), 2005-2010 Figure 17: UTI Therapeutics Market, Germany, Forecast ($m), 2010-2018 Figure 18: UTI Therapeutics Market, Italy, Revenue ($m), 2005-2010 Figure 19: UTI Therapeutics Market, Italy, Forecast ($m), 2010-2018 Figure 20: UTI Therapeutics Market, Spain, Revenue ($m), 2005-2010 Figure 21: UTI Therapeutics Market, Spain, Forecast ($m), 2010-2018 Figure 22: UTI Therapeutics Market, The UK, Revenue ($m), 2005-2010 Figure 23: UTI Therapeutics Market, The UK, Forecast ($m), 2010-2018 Figure 24: UTI Therapeutics Market, Japan, Revenue ($m), 2005-2010 Figure 25: UTI Therapeutics Market, Japan, Forecast ($m), 2010-2018 Figure 26: UTI Therapeutics Market , Key Events Impacting the Future Market Figure 27: Opportunity and Unmet Need in the UTI Therapeutics Market, 2011 Figure 28: UTI Therapeutics - Strategic Competitor Assessment, 2011 Figure 29: UTI Therapeutics - Pipeline by Phase of Clinical Development, 2011 Figure 30: UTI Therapeutics Market - Clinical Pipeline by Mechanism of Action, 2011 Figure 31: Technology Trends Analytical Framework of the UTI Pipeline, 2011 Figure 32: Technology Trends Analytical Framework of The UTI Therapeutics Pipeline Description, 2011 Figure 33: UTI Therapeutics - Clinical Trials by Country, 2011 Figure 34: UTI Therapeutics - Clinical Trials by Phase, 2011 Figure 35: UTI Therapeutics - Clinical Trials by Status, 2011 Figure 36: UTI Therapeutics - Overall Sponsors, 2011 Figure 37: UTI Therapeutics - Prominent Sponsors, 2011 Figure 38: UTI Therapeutic Clinical Trial - Company Sponsors by Phase, 2011 Figure 39: Implications for Future Market Competition in the UTI Therapeutics Market, 2011 Figure 40: UTI Therapeutics Market - Clinical Pipeline by Company, 2011 Figure 41: GlobalData Market Forecasting Model
Report Price: Licence Type Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
Price
$ 3995
Site Licence
$ 7990
Enterprise Wide Licence
$ 11985
Related Reports: Diabetic Gastroparesis Therapeutics - Pipeline Assessment and Market Forecasts to 2019
Pancreatitis Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Polycystic Kidney Disease (PKD) Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Social Anxiety Disorders (SAD) Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Psychotic Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Panic Disorder Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Tourette Syndrome Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Myasthenia Gravis Therapeutics - Pipeline Assessment and Market Forecasts to 2019 Infantile Spasms Therapeutics - Pipeline Assessment and Market Forecasts to 2019
You can order this report by calling on +91 - 998 7295 242 or mail us your contact details at contact@jsbmarketresearch.com About JSB Market Research:JSB market research is a leading player in the market of research report distribution. It is onestop-shop for all information related to market research for any sector of the industry. Along with providing in-depth analysis though reports, JSB market research also provides regular updates of the market though newsletters. Our reports are a well-researched work of market researchers with an extensive knowledge and a good level of market experience.
To know more on Urinary Tract Infections (UTI) Therapeutics - Pipeline Assessment and Market Forecasts to 2018 Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/
http://www.jsbmarketresearch.com/healthcare-medical/r-urinary-tractinfections-uti-therapeutics-pipeline-assessment-and-market-forecasts-135250
Email ID- contact@jsbmarketresearch.com Tel No- 91 2241236650 Published by- http:/www.jsbmarketresearch.com/